Odaia provides Maptual, an AI-powered commercial insights SaaS platform for pharmaceutical companies. The product uses proprietary data-driven and AI-powered methods to identify distinct population subsets and their healthcare providers. With Maptual, pharma sales reps can engage with healthcare providers, sales managers can coach their teams, and marketers can gain a deep understanding of their market and develop targeted campaigns. Led by CEO and co-founder Philip Poulidis, the company is based in Toronto, Canada. The company intends to use the recently raised funds to evolve its product and build out its team. ODAIA offers MAPTUAL, a SaaS commercial insights platform that combines data analysis, process mining and AI to deliver predictive analytics for pharmaceutical commercial teams. The platform analyzes prescriber transactions, anonymized patient health claims, population demographic and socioeconomic data, anonymized lab data and related sources to prioritize and dynamically segment physicians. ODAIA’s tools aim to help pharma determine what they need to know about prescribers so they can deliver the right message through the best channels to reach patients. The company plans to evolve into a one-stop shop for multivariate data analysis and real-time predictive insights across life sciences data and to expand platform integration partnerships. Financially, ODAIA raised a $13.8M Series A and previously completed a $1.6M seed in 2019; the new capital will be used to enhance platform features and expand sales, marketing and customer success teams. Founded at the University of Toronto in 2018, the startup doubled the size of its team over the past year. Odaia builds Maptual, a customer engagement platform that integrates data from all customer touchpoints, including prescription transactions, to provide real-time, personalized insights and actions for pharmaceutical companies. The company uses process mining, customer journey mapping, and artificial intelligence to deliver sales and marketing insights and process automation tools to enterprise customers. Maptual publicly launched in early 2021 and is currently being used by four of the 10 largest global pharmaceutical companies. Odaia has focused its efforts on pharma, which now represents about 95 percent of its business focus, though it is exploring other segments such as e-commerce. The startup plans to add new features including a sales rep portal to bring predictive insights into the field. Proceeds from recent fundraising were intended to support engineering and the rollout of new products and features. ODAIA offers a data analytics, process-mining and machine learning SaaS platform that analyzes customer touchpoints to help companies understand and act on customer journeys. The company layers process-mining techniques with predictive algorithms to deliver explainable (non–black-box) insights. A cited use case is an IoT service provider customer that uses ODAIA to assess engagement and predict attrition among millions of subscribers. Founded in 2018 as a University of Toronto spinout, ODAIA validated its algorithms with customers before productizing them. The startup has nine employees and raised $1.6M in seed funding to fuel development, grow its engineering and ML teams, and support customer deployments. ODAIA plans a public launch of its SaaS platform in 2020 and seeks to become the AI platform across all customer touchpoints to drive efficiencies and revenue growth.

Total raised

$44M

Funding rounds

4

Latest round

Series B

Latest activity

May 2023